Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (BIO3)

  • STATUS
    Recruiting
  • End date
    Mar 24, 2025
  • participants needed
    286
  • sponsor
    University Hospital, Strasbourg, France
Updated on 24 July 2022
methotrexate
rituximab
adalimumab
tofacitinib
infliximab
tumor necrosis factor
etanercept
hydroxychloroquine
DMARD
sulfasalazine
golimumab
certolizumab pegol
leflunomide
abatacept
baricitinib
tocilizumab
rheumatoid factor
cyclic citrullinated peptide antibody

Summary

Approximately, 40 to 50% of patients with rheumatoid arthritis (RA), the most frequent inflammatory arthritide, are non responders to the consensual 1st line of treatment : methotrexate. In these patients, it is well demonstrated that the addition of other immunomodulatory drug(s) often results in a significant improvement. However, the best option regarding the drug(s) to add remains unclear. Rheumatologists are currently used to adding a targeted therapy, such as anti-TNFα, and more recently abatacept or tocilizumab. Triple therapy using 3 conventional disease-modifying drugs (DMARDs), methotrexate or leflunomide+salazopyrine+hydroxychloroquine could be an alternative option to targeted therapies, all the more as they have a more favorable safety profile and a much lower cost. Uncertainty remains regarding the superiority of targeted therapies on triple therapy in methotrexate or leflunomide insufficient responders (IR). Investigators decided to address this issue by performing a randomized controlled pragmatic trial.

Details
Condition Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
Treatment Methotrexate + biologic administration, methotrexate + salazopyrine + hydroxychloroquine administration, Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
Clinical Study IdentifierNCT02714634
SponsorUniversity Hospital, Strasbourg, France
Last Modified on24 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient with rheumatoid arthritis according to EULAR/ACR 2010 criteria
DAS28-CRP>3.2
Insufficient response to methotrexate at a weekly dose≥15mg after at least 3 months or to leflunomide at a dose of 10 (in case 20 mg are not well tolerated) to 20 mg per day after 3 months of treatment
RA radiographic erosions and/or serum rheumatoid factor associated to anti-Cyclic Citrullinated Peptide (Anti-CCP)
Age greater or equal to 18 years
Written informed consent, dated and signed before initiating any trial-related procedure
Affiliation to a social insurance system
Women of child bearing potential, negative β-HCG assay (Human chorionic gonadotropin)
Effective method of birth control during the study and continuing after the discontinuation of the investigational drug or study. The duration will depend on the drug used (referred to the summary product characteristic)

Exclusion Criteria

Previous treatment with or contraindication to targeted therapies (biologic or JAK/STAT inhibitor)
Previous treatment with triple therapy
Other inflammatory arthritis except RA associated with Sjögren's syndrome
Contraindication to all biologics/ JAK/STAT inhibitors or to methotrexate, leflunomide, sulfasalazine and hydroxychloroquine
Corticosteroids at a dose >15 mg/d of equivalent prednisone for at least 4 weeks before the inclusion
Absence of tuberculosis screening
Patient who cannot be followed during 12 months
Pregnancy, breastfeeding, desire of pregnancy in the 12 months
Drug addiction, addiction to alcohol
Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment
Women of child bearing potential, unless they are using an effective method of birth control
Patient under law protection
Prisoners
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note